Vaxxinity, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VAXX research report →
Companywww.vaxxinity.com
Vaxxinity, Inc. , a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD.
- CEO
- Mei Mei Hu
- IPO
- 2021
- Employees
- 57
- HQ
- Dallas, TX, US
Price Chart
Valuation
- Market Cap
- $63.39K
- P/E
- -1.11
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.15%
- ROIC
- -203.71%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-56,934 · 99.92%
- EPS
- $-0.00 · 99.92%
- Op Income
- $-58,285,000
- FCF YoY
- -0.43%
Performance & Tape
- 52W High
- $0.20
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 3.78
- Avg Volume
- 14.23K
Get TickerSpark's AI analysis on VAXX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 1, 23 | Ray Sumita | other | 425,000 |
| Nov 3, 23 | Paula Molina Rene | other | 0 |
| Oct 2, 23 | Powchik Peter | other | 159,744 |
| Oct 1, 23 | Ray Sumita | other | 0 |
| Sep 6, 23 | Prime Movers Lab Fund I LP | sell | 5,308 |
| Sep 7, 23 | Prime Movers Lab Fund I LP | sell | 20,312 |
| Sep 8, 23 | Prime Movers Lab Fund I LP | sell | 25,089 |
| Sep 6, 23 | Prime Movers Lab Fund I LP | sell | 2,189 |
| Sep 7, 23 | Prime Movers Lab Fund I LP | sell | 8,378 |
| Sep 8, 23 | Prime Movers Lab Fund I LP | sell | 10,349 |
Our VAXX Coverage
We haven't published any research on VAXX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VAXX Report →